Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has significantly increased the capacity of its U.K. facilities.
The expansion has been driven by client demand and coincides with the establishment of an expanded panel of immuno-oncology services at Crown Bioscience’s European base, including bioluminescent imaging of popular syngeneic cell line models.
“This is yet another example of Crown Bioscience’s continued success and overall growth as well as our commitment to meet the needs of our European clients,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “This expansion, both in terms of capacity and personnel, will help us accommodate the huge industry demand for syngeneic models, and also provide us with the capacity we need to continue to introduce new oncology models that researchers demand.”
The expansion enables Crown Bioscience to diversify its global portfolio of syngeneic models into orthotopic variants. The U.K. team has an established focus on hormone-associated cancers, such as prostate and breast cancer.